Product Description
TMEM16A Antibody [DG1/1486] | 33-817 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: A recombinant human protein corresponding to amino acids 2-101 of human DOG1 was used as the immunogen for this DOG1 antibody.
Research Area: Signal Transduction
Tested Application: WB, Flow, IHC-P, IF
Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
IF: 0.5-1 ug/ml
IHC (FFPE) : 0.5-1 ug/ml for 30 minutes at RT
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the DOG1 antibody to be titered up or down for optimal performance.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: DG1/1486
Isotype: IgG2b, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: TMEM16A Antibody: DOG1, TAOS2, ORAOV2, TMEM16A, DOG1, Anoctamin-1, Discovered on gastrointestinal stromal tumors protein 1
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: Expression of DOG-1 protein is elevated in the gastrointestinal stromal tumors (GIST s) , c-kit signaling-driven mesenchymal tumors of the GI tract. DOG-1 is rarely expressed in other soft tissue tumors, which, due to appearance, may be difficult to diagnose. Immunoreactivity for DOG-1 has been reported in 97.8 percent of scorable GIST s, including all c-kit negative GIST s. Overexpression of DOG-1 has been suggested to aid in the identification of GISTs, including Platelet-Derived Growth Factor Receptor Alpha mutants that fail to express c-kit antigen. The overall sensitivity of DOG1 and c-kit in GIST s is nearly identical: 94.4% vs. 94.7%.